EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Artificial intelligence in drug discovery: Integrating data, models, and mechanisms for next-generation therapeutics

Rajashekar Korutla, Tanisha Garg, Shridhar Sunilkumar Pol, Venkatesh Shivandi, Samuel Gnanam, Kumara Swamy Padari, Saeed Amal

Artificial Intelligence in the Life Sciences · 2026-12 · 10 · 100183

DOI: 10.1016/j.ailsci.2026.100183 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Artificial Intelligence in the Life Sciences, 2026-12. Verfasst von Rajashekar Korutla und 6 weiteren Autor:innen. Die Arbeit nennt 310 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Artificial intelligence (AI) offers strong promise for accelerating drug discovery, from target identification to lead optimization and toxicity prediction. Over the past decade it has produced real advances in protein structure prediction, billion-compound virtual screening, and generative molecular design. And yet, despite these advances, the translation of AI-predicted compounds into clinically successful drugs remains limited. No drug discovered primarily through AI has reached the market, indicating that the most consequential gaps lie in clinical translation rather than in early-stage design. This review provides a critical synthesis of the past decade’s progress in AI for drug discovery, analyzing tools such as machine learning, generative models, and structure-based design. Key breakthroughs such as AlphaFold, Deep Docking, and GENTRL are highlighted alongside persistent limitations, including data quality and scarcity, limited interpretability, weak generalization, and a shortage of prospective wet-lab validation. We further explore emerging strategies like foundation models, multimodal learning, and active learning that aim to narrow these gaps. By juxtaposing technological achievements with the data, validation, and ethical challenges that still constrain the field, this review offers a realistic roadmap for the responsible and measured integration of AI in pharmaceutical science.

Zitieren

APA

Korutla, R., Garg, T., Pol, S. S., Shivandi, V., Gnanam, S., Padari, K. S., & Amal, S. (2026). Artificial intelligence in drug discovery: Integrating data, models, and mechanisms for next-generation therapeutics. Artificial Intelligence in the Life Sciences, 10, 100183. https://doi.org/10.1016/j.ailsci.2026.100183

Vancouver

Korutla R, Garg T, Pol SS, Shivandi V, Gnanam S, Padari KS, et al. Artificial intelligence in drug discovery: Integrating data, models, and mechanisms for next-generation therapeutics. Artificial Intelligence in the Life Sciences. 2026;10:100183. doi:10.1016/j.ailsci.2026.100183

BibTeX
@article{Korutla2026,
  author = {Korutla, Rajashekar and Garg, Tanisha and Pol, Shridhar Sunilkumar and Shivandi, Venkatesh and Gnanam, Samuel and Padari, Kumara Swamy and Amal, Saeed},
  title = {Artificial intelligence in drug discovery: Integrating data, models, and mechanisms for next-generation therapeutics},
  journal = {Artificial Intelligence in the Life Sciences},
  year = {2026},
  volume = {10},
  pages = {100183},
  doi = {10.1016/j.ailsci.2026.100183}
}
Kostenlos starten →